EAST

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1722	((544/323) or (514/275)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/09/25 11:50

NPL

NCBI PubMed National Library of Medicine NLM

My N
[Sign In] [Regi

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for #1 and #2 Preview Go Cl

Limits Preview/Index **History** Clipboard Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Search	Most Recent Queries	Time	Result
#3	Search **#1 and #2**	11:54:53	11
#2	Search **stimulating neuronal function**	11:54:40	1359
#1	Search **pyrimidine**	11:53:45	137453

Clear History

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Sep 14 2005 04:34:46

Items 1 - 11 of 11 One page.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Petroff BK, Croutch CR, Hunter DM, Wierman ME, Gao X. Related Articles, Links

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) stimulates gonadotropin secretion in the immature female Sprague-Dawley rat through a pentobarbital- and estradiol-sensitive mechanism but does not alter gonadotropin-releasing hormone (GnRH) secretion by immortalized GnRH neurons in vitro.
Biol Reprod. 2003 Jun;68(6):2100-6. Epub 2003 Jan 22.
PMID: 12606454 [PubMed - indexed for MEDLINE]

2: Klementiev B, Bichevaja N, Novikova T, Chebotar N, Bock E, Berezin V. Related Articles, Links

A peptide agonist of the neural cell adhesion molecule (NCAM), C3, protects against developmental defects induced by a teratogen pyrimethamine.
Int J Dev Neurosci. 2002 Nov;20(7):527-36.
PMID: 12485621 [PubMed - indexed for MEDLINE]

3: Mignon L, Wolf WA. Related Articles, Links

Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
Psychopharmacology (Berl). 2002 Aug;163(1):85-94. Epub 2002 Jul 13.
PMID: 12185404 [PubMed - indexed for MEDLINE]

4: Spencer JP, Whiteman M, Jenner P, Halliwell B. Related Articles, Links

5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons.
J Neurochem. 2002 Apr;81(1):122-9.
PMID: 12067224 [PubMed - indexed for MEDLINE]

5: Fiorica-Howells E, Maroteaux L, Gershon MD. Related Articles, Links

Serotonin and the 5-HT(2B) receptor in the development of enteric neurons.
J Neurosci. 2000 Jan 1;20(1):294-305.
PMID: 10627607 [PubMed - indexed for MEDLINE]

6: Markianos M, Hatzimanolis J, Lykouras L. Related Articles, Links

Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone.
Psychopharmacology (Berl). 1999 Apr;143(3):270-2.
PMID: 10353429 [PubMed - indexed for MEDLINE]

7: Lochhead KM, Zager RA. Related Articles, Links

Fluorinated anesthetic exposure "activates" the renal cortical sphingomyelinase cascade.
Kidney Int. 1998 Aug;54(2):373-81.
PMID: 9690203 [PubMed - indexed for MEDLINE]

8: Xu F, Frazier DT. Related Articles, Links

Medullary respiratory neuronal activity modulated by stimulation of the fastigial nucleus of the cerebellum.
Brain Res. 1995 Dec 24;705(1-2):53-64.
PMID: 8821733 [PubMed - indexed for MEDLINE]

9: De Gennaro Colonna V, Bertola G, Coco CB, Bifano M, Cocchi D, Maggi A, Muller EE. Related Articles, Links

Changes in the hypothalamic-pituitary somatotropic function of infant hypothyroid rats.
Proc Soc Exp Biol Med. 1990 Mar;193(3):214-9.
PMID: 1968255 [PubMed - indexed for MEDLINE]

10: Gottesfeld Z, Butler IJ, Findley WE. Related Articles, Links

Prenatal and postnatal hypothyroidism abolishes lesion-induced noradrenergic sprouting in the adult rat.
J Neurosci Res. 1985;14(1):61-9.
PMID: 4020898 [PubMed - indexed for MEDLINE]

11: Gotz D, Ziesch C, Wenzel M, Grosse G, Schuster T, Wenzel J. Related Articles, Links

[Electron microscopic and morphometric studies on the in vitro differentiation of mitochondria in neurons of hippocampus explant cultures as affected by orotic acid and sodium orotate]
Z Mikrosk Anat Forsch. 1982;96(4):613-32. German.
PMID: 6184903 [PubMed - indexed for MEDLINE]

Display Summary Show 20 Sort by Send to

10648046

C:\STNEXP4\QUERIES\~~09907273~~ (subgenus).str





chain nodes :
7 8 9 10 12 16
ring nodes :
1 2 3 4 5 6
chain bonds :
2-16 6-7 7-8 8-9 9-10 9-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-16 6-7 7-8 9-10 9-12
exact bonds :
8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
12:CLASS 16:CLASS

10/648,046
~~09/907,273~~ (subgenus around elected species)

```
=>
Uploading 09907273.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 O,N


Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:19:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   5610 TO ITERATE

 17.8% PROCESSED    1000 ITERATIONS                          21 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       107712 TO   116688
PROJECTED ANSWERS:            1705 TO     3007

L2            21 SEA SSS SAM L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045

L3    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09907273.str

L4      STRUCTURE UPLOADED

=> que L4 NOT L3

L5   QUE L4 NOT L3

=> d l5
```

10/648,046

~~09/907,273~~ (subgenus around elected species)

L5 HAS NO ANSWERS
L3 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045
L4 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.
L5 QUE L4 NOT L3

=> s l5 sss sam
SAMPLE SEARCH INITIATED 18:25:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 446 TO ITERATE

100.0% PROCESSED 446 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7653 TO 10187
PROJECTED ANSWERS: 964 TO 1996

L6 50 SEA SSS SAM L4 NOT L3

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L7 SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09907273 (subgenus).str

L8 STRUCTURE UPLOADED

=> que L8 NOT L7

L9 QUE L8 NOT L7

10/648,046

~~09/907,273~~ (subgenus around elected species)

```
=> d l9
L9 HAS NO ANSWERS
L7              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045
L8              STR
```




```
G1 O,N


Structure attributes must be viewed using STN Express query preparation.
L9              QUE  L8 NOT L7


=> s l9 sss sam
SAMPLE SEARCH INITIATED 18:27:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     368 TO ITERATE

100.0% PROCESSED     368 ITERATIONS                                 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          6210 TO     8510
PROJECTED ANSWERS:              964 TO     1996

L10         50 SEA SSS SAM L8 NOT L7

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045

L11   SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\09907273 (subgenus).str

L12     STRUCTURE UPLOADED

=> que L12 NOT L11

L13  QUE L12 NOT L11
```

```
=> d l13
L13 HAS NO ANSWERS
L11             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045
L12             STR
```




```
G1 O,N


Structure attributes must be viewed using STN Express query preparation.
L13             QUE  L12 NOT L11


=> s l13 sss sam
SAMPLE SEARCH INITIATED 18:28:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     47 TO ITERATE

100.0% PROCESSED      47 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          529 TO     1351
PROJECTED ANSWERS:               3 TO      163

L14           3 SEA SSS SAM L12 NOT L11

=> s l13 sss ful
FULL SEARCH INITIATED 18:30:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1276 TO ITERATE

100.0% PROCESSED    1276 ITERATIONS                              88 ANSWERS
SEARCH TIME: 00.00.01

L15          88 SEA SSS FUL L12 NOT L11

=> s l15
L16         40 L15

=> d l16 1-40 bib,ab,hitstr
```

10/648,046
~~09/907,273~~ (subgenus around elected species)

L16 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2003:76625 CAPLUS
DN 138:122653
TI Pyrimidine derivatives for treatment of neurodegenerative diseases
IN Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003007963	A1	20030130	WO 2002-US23246	20020717

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-907273 A 20010717 ← Applicant's.

AB A pyrimidine deriv. or analog comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker -L-C(O)- to a moiety B, where C(O)-B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including H or alkyl, and D is a moiety that enhances the pharmacol. effects, promotes absorption, or promotes blood-brain barrier penetration of the deriv. or analog. The moiety A can have two or three N atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two N atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biol. or physiol. activity. All cited compds. (e.g. 4-[[3-[(2-amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid Et ester) have nootropic or antiamnestic activity at doses of 10 mg/kg i.p. or less. Although the methods of prepn. are not claimed, 3 example prepns. are included.

IT **389799-47-7P**, 4-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic Acid Ethyl Ester **389799-50-2P**, 4-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid **389799-54-6P**, 3-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid ethyl ester **389799-57-9P**, 3-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; pyrimidine derivs. for treatment of neurodegenerative diseases)

RN 389799-47-7 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-50-2 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 389799-54-6 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Elected species!



RN 389799-57-9 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2002:215776 CAPLUS
DN 137:70674
TI Amino-substituted O6-benzyl-5-nitrosopyrimidines: interplay of molecular, molecular-electronic and supramolecular structures
AU Quesada, Antonio; Marchal, Antonio; Melguizo, Manuel; Nogueras, Manuel; Sanchez, Adolfo; Low, John N.; Cannon, Debbie; Farrell, Dorcas M. M.; Glidewell, Christopher
CS Departamento de Quimica Inorganica y Organica, Universidad de Jaen, Jaen, 23071, Spain
SO Acta Crystallographica, Section B: Structural Science (2002), B58(2), 300-315
CODEN: ASBSDK; ISSN: 0108-7681
PB Blackwell Munksgaard
DT Journal
LA English
AB The structures of eight 2,4,6-trisubstituted-5-nitrosopyrimidines (one of which crystallizes in two polymorphs) were detd., including seven O6-benzyl derivs. which are potential, or proven, in vitro inhibitors of the human DNA-repair protein O6-alkylguanine-DNA-transferase. In the derivs. having an amino substituent at the 4-position, an intramol. N-H...O H bond with the nitroso O as an acceptor leads to an overall mol. shape similar to that of substituted purines. There is a marked propensity for these nitroso compds. to crystallize with Z' = 2. The structure of an analog with no nitroso group is also reported for comparative purposes. Compds. contg. the N-alkyl substituents -NHCH2COOEt, -NHCH2CH2COOEt and -NHCH(CH2Ph)COOEt, derived from amino acid esters, exhibit a rich variety of conformational behavior, and in all of the nitroso compds. the bond lengths provide strong evidence for a highly polarized electronic structure. Assocd. with this polarization is extensive charge-assisted H bonding between the mols., leading to supramol. aggregation as finite (zero-dimensional) aggregates, chains, mol. ladders, sheets and frameworks.
IT **439666-61-2 439666-62-3 439666-63-4**
RL: PRP (Properties)
(crystal structure of)
RN 439666-61-2 CAPLUS
CN Glycine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 439666-62-3 CAPLUS
CN .beta.-Alanine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 439666-63-4 CAPLUS
CN L-Phenylalanine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51464 CAPLUS
DN 136:112673
TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for treatment of disease-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004452	A2	20020117	WO 2001-US21526	20010706
WO 2002004452	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002055506	A1	20020509	US 2001-900844	20010706 — AU 1617
US 2002061899	A1	20020523	US 2001-899901	20010706 — AU 1614
PRAI US 2000-216844P	P	20000707		

OS MARPAT 136:112673
AB A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.
IT **389799-47-7 389799-50-2 389799-54-6**
389799-57-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of disease-induced peripheral neuropathy and related conditions)
RN 389799-47-7 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-50-2 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 389799-54-6 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51463 CAPLUS
DN 136:112672
TI Methods using a purine derivative,pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system
IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English

not prior as Appln abandoned

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004451	A2	20020117	WO 2001-US21385	20010706
WO 2002004451	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002040032 A1 20020404 US 2001-899478 20010705 ← E. Abn. (1614).

PRAI US 2000-216808P P 20000707
OS MARPAT 136:112672
AB A method of increasing the synthesis and/or secretion of synaptphysin comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. of analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.
IT **389799-47-7 389799-50-2 389799-54-6**
389799-57-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine deriv.,pyrimidine deriv., or tetrahydroindolone deriv. for stimulation of synthesis of synaptophysin in CNS)
RN 389799-47-7 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-50-2 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 389799-54-6 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51462 CAPLUS
DN 136:112671
TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid .beta. peptide in the central nervous system
IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004450	A2	20020117	WO 2001-US21384	20010706
WO 2002004450	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002040031	A1	20020404	US 2001-899611	20010705
PRAI US 2000-216845P	P	20000707		

1614.

OS MARPAT 136:112671
AB A method of either inhibiting the formation of A.beta. or stimulating the formation of sAPP comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.
IT **389799-47-7 389799-50-2 389799-54-6 389799-57-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for prevention of accumulation of amyloid .beta. peptide in CNS)
RN 389799-47-7 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-50-2 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 389799-54-6 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 6 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51461 CAPLUS
DN 136:112691
TI Methods using a purine derivative, a pyrimidine derivative or a tetrahydroindolone derivative for treatment of conditions affected by activity of multidrug transporters
IN Taylor, Eve M.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004449	A2	20020117	WO 2001-US21383	20010706
	WO 2002004449	A3	20020613		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002128264	A1	20020912	US 2001-900297	20010706
PRAI	US 2000-216616P	P	20000707		

← E. Abm. (1617)

OS MARPAT 136:112691
AB One aspect of the invention is a method of treating a condition or disease assocd. with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease assocd. with the activity of a multidrug transporter protein an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer, a microbial or parasitic infection, HIV, infection, or a condition assocd. with inflammation, e.g. asthma or rheumatic disease.
IT **389799-47-7 389799-50-2 389799-54-6 389799-57-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine deriv., pyrimidine deriv. or tetrahydroindolone deriv. for treatment of conditions affected by activity of multidrug transporters)
RN 389799-47-7 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-50-2 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 389799-54-6 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51460 CAPLUS
DN 136:112670
TI Methods using purine derivatives, pyrimidine derivatives, and tetrahydroindolone derivatives for treatment of drug-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English

Same as #3

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002055506	A1	20020509	US 2001-900844	20010706 ✓
	US 2002061899	A1	20020523	US 2001-899901	20010706 ✓
PRAI	US 2000-216844P	P	20000707		

OS MARPAT 136:112670

AB A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy assocd. with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly useful in treating peripheral neuropathy assocd. with the administration of vincristine, paclitaxel, or cisplatin.

IT **389799-47-7 389799-50-2 389799-54-6**
389799-57-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of drug-induced peripheral neuropathy and related conditions)

RN 389799-47-7 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-50-2 CAPLUS
CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 389799-54-6 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS
CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2001:345113 CAPLUS
DN 135:12332
TI N-(2-Amino-1,6-dihydro-5-nitroso-6-oxopyrimidin-4-yl)-L-isoleucine-water(4/1): interplay of molecular and supramolecular structures
AU Low, John N.; Cannon, Debbie; Quesada, Antonio; Marchal, Antonio; Melguizo, Manuel; Nogueras, Manuel; Sanchez, Adolfo; Glidewell, Christopher
CS Department of Chemistry, University of Aberdeen, Meston Walk, Old Aberdeen, AB24 3UE, UK
SO Acta Crystallographica, Section C: Crystal Structure Communications (2001), C57(5), 604-607
CODEN: ACSCEE; ISSN: 0108-2701
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
AB In the title compd., 2C10H15N5O4.cntdot.0.5H2O, there are two independent mols. of the pyrimidinylisoleucine in general positions and a H2O mol. lying on a 2-fold rotation axis. The bond lengths within the org. moieties demonstrate significant polarization of the electronic structure. Each of the org. mols. participates in 12 intermol. H bonds, of O-H...O and N-H...O types, while the H2O mol. acts as a double donor and as a double acceptor of O-H...O H bonds. The org. components are linked by the H bonds into a single three-dimensional framework, reinforced by the H2O mols. Crystallog. data are given.
IT **340993-79-5**
RL: PRP (Properties)
(prepn. and crystal structure)
RN 340993-79-5 CAPLUS
CN L-Isoleucine, N-(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)-, hydrate (4:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/4 H_2O

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 2000:84798 CAPLUS
DN 132:137383
TI Preparation of pyrazole derivatives as antitumor agents
IN Ejima, Akio; Ohsuki, Satoru; Ohki, Hitoshi; Naito, Hiroyuki; Makino, Chie
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005230	A1	20000203	WO 1999-JP3962	19990723
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9948002	A1	20000214	AU 1999-48002	19990723
	EP 1103551	A1	20010530	EP 1999-931515	19990723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2000169475	A2	20000620	JP 1999-211211	19990726
	NO 2001000405	A	20010322	NO 2001-405	20010123
PRAI	JP 1998-208807	A	19980724		
	JP 1998-274459	A	19980929		
	WO 1999-JP3962	W	19990723		

OS MARPAT 132:137383
AB The title compds. I [R1 = H, halo, etc.; R2 = H, halo, OH, etc.; R3 = H, amino, alkoxy, etc.; R4 = H, halo, alkylamino, etc.; R5 = H, alkyl, etc.; Q = heterocyclic ring, etc.; G = heterocyclic ring (further details on said ring are given)] are prepd. Compds. of this invention in vitro showed IC50 values of 0.6 ng/mL to 35 ng/mL against the growth of lung tumor cells.
IT **256929-34-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazole derivs. as antitumor agents)
RN 256929-34-7 CAPLUS
CN Glycine, N-[2-amino-6-[4-[(1E)-3-[4-(3,5-difluorophenyl)-1-piperazinyl]-1-propenyl]-5-methyl-1H-pyrazol-1-yl]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.


H2N
N
H
N
CO2H
N
N
N
Me
E
N
N
F
F
● HCl

L16 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1994:435156 CAPLUS
DN 121:35156
TI Cyclodehydration of 5-[(Carboxymethyl)amino]pyrimidines. Synthesis and Characterization of Novel Mesoionic Imidazo[1,2-c]pyrimidin-3-ones
AU Edstrom, Eric D.; Wei, Yuan; Gordon, Michelle
CS Department of Chemistry and Biochemistry, Utah State University, Logan, UT, 84322-0300, USA
SO Journal of Organic Chemistry (1994), 59(9), 2473-81
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
AB The cyclodehydration of 5-(carboxymethyl)amino-substituted pyrimidines I (R1 = SMe, NH2) using acid anhydrides provided a general prepn. of novel mesoionic imidazo[1,2-c]pyrimidin-3-one compds., for example II (same R1). Compds. lacking a blocking group at N-1 undergo clean alkylation at this position, under basic reaction conditions, with substituted alkyl chlorides. Imidazo[1,2-c]pyrimidin-3-ones having a benzyl group at N-1 were found to undergo substitution reactions on the pyrimidine ring in the presence of basic nucleophiles. Thus, replacement of a 5-methylthio over a 7-chloro substituent was favored, whereas the 7-chloro group was substituted in compds. where a 5-amino substituent was present. Exposure of imidazo[1,2-c]pyrimidin-3-ones to aq. acid results in the ring opening of the 5-membered ring with loss of CO2 in an overall net reversion of the cyclodehydration reaction. Examn. of the x-ray structures obtained for some II indicated that the 5-membered ring was not arom., but rather a combination of a ring-opened valence tautomer and a charge-delocalized resonance hybrid structure.
IT **155670-18-1P 155670-23-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for imidazo[1,2-c]pyrimidinone resonance hybrid)
RN 155670-18-1 CAPLUS
CN Glycine, N-(2-amino-6-chloro-4-pyrimidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 155670-23-8 CAPLUS
CN Glycine, N-(2-amino-6-chloro-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L16 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1993:234397 CAPLUS
DN 118:234397
TI Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase
AU Chern, Ji Wang; Lee, Horng Yuh; Chen, Chien Shu; Shewach, Donna S.; Daddona, Peter E.; Townsend, Leroy B.
CS Med. Lab., Natl. Def. Med. Cent., Taipei, 100, Taiwan
SO Journal of Medicinal Chemistry (1993), 36(8), 1024-31
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB In an effort to develop potent human purine nucleoside phosphorylase (PNP) inhibitors as immunosuppressive and chemotherapeutic agents, several 8-aminoguanine derivs., e.g. I [R = (CH2)5Me, (CH2)5CO2H, R1-R3, R4 = OH, SPh (II), R5 = iodo, COC6H4SO2F-4], and formycin derivs. III (R6 = SPh, COC6H4SO2F-4), were synthesized and evaluated as potential PNP inhibitors. These studies were designed to investigate the hydrophobic effect of a substituent on the N-9 of the purine heterocycle and/or the C-5' positions. The affinity of these compds. to erythrocytic PNP was detd. and none of these compds. showed a better affinity than those of the parent compds. The effect of hydrophobicity at the N-9 and the C-5' positions might play an important role in binding to the active site of PNP. Thus, compd. II was found to be the best inhibitor in this series.
IT **146203-16-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and ring closure of)
RN 146203-16-9 CAPLUS
CN Hexanoic acid, 6-[[2-amino-1,6-dihydro-5-[[[(methoxycarbonyl)amino]thioxomethyl]amino]-6-oxo-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1991:675113 CAPLUS
DN 115:275113
TI A novel theory of tripartate conjugate and its application to synthesize soluble macromolecular conjugates
AU Bhattacharyya, A.
CS Div. Biochem. Eng., Indian Inst. Chem. Biol., Calcutta, 700 032, India
SO Journal of the Indian Chemical Society (1991), 68(3), 172-4
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
AB A scheme was designed by which a tripartite conjugate can be constructed. The conjugate is designed as a ligand-bridge-protein. The insol. org. compd. (ligand) is coupled to a macromol. (protein) via a very hydrophilic water-sol. mol. (bridge). It was found that citric acid can be an effective bridge.
IT **137682-09-8P**
RL: PREP (Preparation)
(prepn. and conjugation with albumin)
RN 137682-09-8 CAPLUS
CN Butanedioic acid, 2-[2-[[2-amino-5-(4-chlorophenyl)-6-ethyl-4-pyrimidinyl]amino]-2-oxoethyl]-2-hydroxy- (9CI) (CA INDEX NAME)



IT **137682-09-8DP**, albumin conjugates
RL: PREP (Preparation)
(prepn. of)
RN 137682-09-8 CAPLUS
CN Butanedioic acid, 2-[2-[[2-amino-5-(4-chlorophenyl)-6-ethyl-4-pyrimidinyl]amino]-2-oxoethyl]-2-hydroxy- (9CI) (CA INDEX NAME)



L16 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1990:591849 CAPLUS
DN 113:191849
TI Isosteric oligonucleotide analogs containing sulfur
IN Benner, Steven Albert
PA Switz.
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8912060	A1	19891214	WO 1989-US2323	19890526
	W: AU, JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 5216141	A	19930601	US 1988-202528	19880606
	AU 8937654	A1	19900105	AU 1989-37654	19890526
	AU 635209	B2	19930318		
	EP 418309	A1	19910327	EP 1989-906936	19890526
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03505452	T2	19911128	JP 1989-506581	19890526
PRAI	US 1988-202528	A	19880606		
	WO 1989-US2323	A	19890526		

AB Oligonucleotides contg. isosteric S linkages instead of a phosphate, e.g. I, which are resistant to chem. and in vivo enzymic degrdn., lipophilic, and thereby easily cross biol. barriers, and thus useful as, e.g. probes for cDNA, can be prepd. from rigid or flexible isosteric building blocks [II, III, and IV; X = O, CH2; R = OH, R1 = SH; or R = SH, R1 = OH; B = heterocycle ring selected from (aza)pyrimidine, (aza)purine, pyrrolopyrimidine, pyrazolopyrimidine, triazolopyrimidine, imidazolopyrimidine, pyrrolopyridine, pyrazolopyridine, and triazolopyridine, which may be functionalized with NH2, HO, halo, acylamino, or acylhydroxy]. Thus, ozonolysis of 2-(pivaloyloxymethyl)cyclohex-4-enol (V; R3 = pivaloyl) (prepn. given) in MeOH and treatment of the resulting 3,4-trans-1-methoxy-3-pivaloyloxymethyl-4-(2'-hydroxyethyl)tetrahydrofuran with Dowex W50 in refluxing PhMe gave a 2,8-dioxa[1.2.3]bicyclooctane (VI) which was stirred 15 h at room temp. with bis(trimethylsilyloxy)pyrimidine in the presence of CF3SO3SiMe3 in MeCN to give II (X = O, R = OH, R1 = pivaloyloxy, B = 1-uracilyl). Reaction of the latter with EtO2CN:NCO2Et, Ph3P, and AcSH in THF gave II (X = O, R = SAc, R1 = pivaloyloxy, B = 1-uracilyl) which could be conveniently stored and deprotected immediately prior to condensation, by redn. with LiBEt3H (super-hydride) in THF to give a bishomonucleoside II (X = O, R = SH, R1 = OH, B = 1-uracilyl). No synthetic examples for I or other oligonucleotides but only synthetic schemes were given. I bind to complementary A-C-C-T-C-C-T (no data).

IT **128435-43-8P 128435-44-9P 128453-43-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for acyclic nucleoside analog)

RN 128435-43-8 CAPLUS
CN Butanoic acid, 4,4'-dithiobis[2-[(2-amino-6-chloro-4-pyrimidinyl)amino]-, dimethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 128435-44-9 CAPLUS
CN Butanoic acid, 4,4'-dithiobis[2-[(2,5-diamino-6-chloro-4-pyrimidinyl)amino]-, dimethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 128453-43-0 CAPLUS
CN Butanoic acid, 4,4'-dithiobis[2-[[2-amino-6-chloro-5-[(4-chlorophenyl)azo]-4-pyrimidinyl]amino]-, dimethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 1-B



L16 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1990:139840 CAPLUS
DN 112:139840
TI Preparation of new peptides as antiviral agents
IN Marumoto, Ryuji; Fukuda, Tsunehiko
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01226899	A2	19890911	JP 1988-54651	19880308
PRAI JP 1988-54651		19880308		

OS MARPAT 112:139840
AB H(NHCHR2CO)l(NHCHR1CONHCHR2CO)m(NHCHR1CO)nOH [R1 = L- or D-.omega.-nucleo-.alpha.-amino acid residue; R2 = L- or D-.alpha.-amino acid residue except .omega.-nucleo-.alpha.-amino acid residue; l, n = 0, 1; m .gtoreq.1 integer], useful as antivirals, esp. useful as inhibitors for HBV virus, and for diagnosis of sicklemia, Down's syndrome, and hepatitis (no data), are prepd. H-L-Ser-(L-willardine)-L-Ser-(L-willardine)-L-Ser-(L-9-adenylalanine)-L-Ser-L-willardine)-L-Ser-(L-9-adenylalanine)-Gly-OH was prepd. using a automated peptide synthesizer by condensing amino acid units such as adenylaminopropionic acid deriv. I (prepn. given).
IT **125883-42-3P 125883-43-4P 125883-45-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of antiviral peptide)
RN 125883-42-3 CAPLUS
CN Butanoic acid, 2-amino-4-[(2-amino-6-chloro-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



RN 125883-43-4 CAPLUS
CN Butanoic acid, 2-amino-4-[(2-amino-6-chloro-5-[(4-chlorophenyl)azo]-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



RN 125883-45-6 CAPLUS
CN Butanoic acid, 2-amino-4-[(2,5-diamino-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1987:214262 CAPLUS
DN 106:214262
TI Bridged isocytosine-adenosine compounds: synthesis and antibacterial evaluation
AU Lever, O. William, Jr.; Vestal, B. Randall
CS Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA
SO Journal of Heterocyclic Chemistry (1986), 23(3), 901-3
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 106:214262
AB Twelve title compds. I (R = NO, NO2; n = 2, 3, 4, 5, 6, 7) were prepd. from the corresponding H2N(CH2)nCO2H by sequential N-benzyloxycarbonylation with PhCH2OCOCl, conversion to active esters by treatment with N-hydroxysuccinimide, amidation with 5'-amino-5'-deoxyadenosine, hydrogenolysis to remove the benzyloxycarbonyl group, and coupling with 6-(methylthio)-5-nitrosoisocytosine or 6-chloro-5-nitroisocytosine. I showed no significant antibacterial activity when tested in vitro against 22 bacterial strains at 30 .mu.g/mL.
IT **108257-25-6P 108257-26-7P 108257-27-8P**
108257-28-9P 108257-30-3P 108257-31-4P
108257-32-5P 108257-33-6P 108282-48-0P
108318-63-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 108257-25-6 CAPLUS
CN Adenosine, 5'-[[3-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxopropyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-26-7 CAPLUS
CN Adenosine, 5'-[[4-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxobutyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-27-8 CAPLUS
CN Adenosine, 5'-[[6-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxohexyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-28-9 CAPLUS
CN Adenosine, 5'-[[7-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxoheptyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-30-3 CAPLUS
CN Adenosine, 5'-[[3-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxopropyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-31-4 CAPLUS
CN Adenosine, 5'-[[4-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxobutyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-32-5 CAPLUS
CN Adenosine, 5'-[[5-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxopentyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-33-6 CAPLUS
CN Adenosine, 5'-[[7-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxoheptyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108282-48-0 CAPLUS
CN Adenosine, 5'-[[5-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxopentyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108318-63-4 CAPLUS
CN Adenosine, 5'-[[6-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxohexyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1986:207022 CAPLUS
DN 104:207022
TI Specific inhibitors in vitamin biosyntheses. Part 8. Syntheses of some functionalized 7,7-dialkyl-7,8-dihydropterins
AU Cameron, Robert; Nicholson, Sydney H.; Robinson, David H.; Suckling, Colin J.; Wood, Hamish C. S.
CS Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, G1 1XL, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1985), (10), 2133-43
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 104:207022
AB The functionalized blocked 7,8-dihydropteridines I (R = OH, R1 = 4-ClC6H4CH2; R = H, R1 = OH, CH2CO2H; R = 2,4,5-Cl3C6H2O, R1 = H) and II were prepd. The functional groups were chosen to provide compds. with potential for investigating the protein chem. of enzymes in the pathway leading to dihydrofolate and, in particular, of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase. The potential of 7-substituents to provide sites of attachment of inhibitors to columns for affinity chromatog. was explored but the extent of the study was curtailed by the restricted applicability of NOCl addn. to alkenes, a reaction used in the synthesis of precursors for I and II. I (R = 2,4,5-Cl3C6H2O, R1 = H) and II were designed to have enhanced transport properties.
IT **102222-95-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization of)
RN 102222-95-7 CAPLUS
CN Hexanoic acid, 4-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-4-methyl-5-oxo- (9CI) (CA INDEX NAME)



L16 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1983:605528 CAPLUS
DN 99:205528
TI Minoxidil sulfate, a metabolite of minoxidil
AU Johnson, Garland A.; Barsuhn, Karen J.; McCall, John M.
CS Cardiovasc. Dis. Res. Cent. Nerv. Syst. Dis. Res., Upjohn Co., Kalamazoo, MI, USA
SO Drug Metabolism and Disposition (1983), 11(5), 507-8
CODEN: DMDSAI; ISSN: 0090-9556
DT Journal
LA English
AB Following the i.v. administration of labeled minoxidil (I) [38304-91-5] to rats, reversed-phase high-pressure liq. chromatog. of bile of I-treated rats confirmed the presence of known I-metabolites as well as a previously unknown metabolite, minoxidil sulfate [83701-22-8]. Minoxidil sulfate comprised a small portion of the total radioactivity in the bile, i.e. 3% of the total, and it produced a distinct peak in the profile of biliary I metabolites.
IT **56828-38-7**
RL: BIOL (Biological study)
(as minoxidil metabolite)
RN 56828-38-7 CAPLUS
CN Pentanoic acid, 5-[(2,6-diamino-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1983:437986 CAPLUS
DN 99:37986
TI Detection of C-nitroso dimer formation by field desorption mass spectrometry
AU Johnson, R. L.; Lever, O. W., Jr.; Brent, D. A.
CS Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA
SO Organic Mass Spectrometry (1983), 18(1), 36-41
CODEN: ORMSBG; ISSN: 0030-493X
DT Journal
LA English
AB Field desorption mass spectrometry showed Me2CClCH(NO)CH2OR (R = cyclohexyl, PhCH2, Me, cyclopentyl) (I-IV, resp.) to exist as dimers whereas p-O2NC6H4NHPh and pyrimidines V [R = Me, (CH2)5CO2H] are monomeric. Mixed dimers of II with I, III, and IV and I with IV were also obsd. using the technique.
IT **86296-76-6**
RL: PRP (Properties)
(mass spectrum of, field desorption)
RN 86296-76-6 CAPLUS
CN Hexanoic acid, 6-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1979:137759 CAPLUS
DN 90:137759
TI The reaction of 2,4-diamino-6-piperidinopyrimidine 3-oxide with acid anhydrides
AU McCall, John M.; TenBrink, Ruth E.; Royer, Max E.; Ko, Howard
CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA
SO Journal of Heterocyclic Chemistry (1978), 15(8), 1529-30
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
AB Reaction of the title compd. I (R = R1 = H) with 1 equiv. of Ac2O gave 26:1 I (R = Ac, R1 = H) and I (R = H, R1 = Ac). Bz2O reacted similarly to give a 16:1 ratio of the corresponding amides. Excess anhydrides gave the diamides. Reaction of I (R = R1 = H) with glutaric anhydride gave only I (R = CO(CH2)3CO2H, R1 = H).
IT **69729-67-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 69729-67-5 CAPLUS
CN Pentanoic acid, 5-[[2-amino-3-oxido-6-(1-piperidinyl)-4-pyrimidinyl]amino]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1977:593445 CAPLUS
DN 87:193445
TI Radioimmunoassay of minoxidil in human serum
AU Royer, Max E.; Ko, Howard; Gilbertson, Terry J.; McCall, John M.; Johnston, Karen T.; Stryd, Ronald
CS Drug Metab. Res. Sect., Upjohn Co., Kalamazoo, MI, USA
SO Journal of Pharmaceutical Sciences (1977), 66(9), 1266-9
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
AB A simple, sensitive, and specific radioimmunoassay for detg. minoxidil (I) [38304-91-5] was developed. Rabbit antiserum to 2 I haptens were compared for cross-reactivity and assay levels on human serums. One antiserum had little cross-reactivity with I metabolites. The radioimmunoassay is specific for detg. I directly in serum without extn. Human serum I levels were detd. from a single oral dose. The limit of detection was 3.02 ng/mL.
IT **64675-16-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and immune cross-reactions of, with minoxidil)
RN 64675-16-7 CAPLUS
CN Pentanoic acid, 5-[[2-amino-3-oxido-6-(1-piperidinyl)-4-pyrimidinyl]amino]-5-oxo- (9CI) (CA INDEX NAME)



L16 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1977:453368 CAPLUS
DN 87:53368
TI 2,4-Diaminopyrimidine derivatives
PA Fabrica Espanola de Productos Quimicos y Farmaceuticos S. A., Spain
SO Span., 9 pp.
CODEN: SPXXAD
DT Patent
LA Spanish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI ES 431918	A1	19761101	ES 1974-431918	19741114
PRAI ES 1974-431918		19741114		

AB Amides I (R = H, X = o-C6H4; R = 3,4,5-(MeO)3C6H2CH2, X = CH:CH, CH2CH2) were prepd. by acylating 2,4-pyrimidinediamines with the appropriate anhydrides.

IT **63271-78-3P 63306-49-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 63271-78-3 CAPLUS
CN Butanoic acid, 4-[[2-amino-5-[(3,4,5-trimethoxyphenyl)methyl]-4-pyrimidinyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 63306-49-0 CAPLUS
CN 2-Butenoic acid, 4-[[2-amino-5-[(3,4,5-trimethoxyphenyl)methyl]-4-pyrimidinyl]amino]-4-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1977:189996 CAPLUS
DN 86:189996
TI 2-Amino-4-(carboxyacylamido)pyrimidine bismuth salts
PA Fabrica Espanola de Productos Quimicos y Farmaceuticos S. A., Spain
SO Span., 8 pp.
CODEN: SPXXAD
DT Patent
LA Spanish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI ES 432523	A1	19760901	ES 1974-432523	19741203
PRAI ES 1974-432523		19741203		

AB The pyrimidine compds. I (R = H, PhCH2 or methoxybenzyl; Z = alkylene, arylene) were converted into the Bi salts by treatment with yellow Bi oxide, freshly prepd. from Bi(NO3)3 and aq. NaOH, in a solvent or mixt. of solvents of 10 .mu. polarity. Thus, a mixt. of I [R = H, Z = (CH2)3] and Bi oxide in 210 L n-hexane and 1.5 L H2O was stored at 65.degree.C for <10 h to give the Bi salt. Also prepd. was the Bi salt of I [R = 3,4,5-(MeO)3C6H2, Z = (CH2)2].

IT **62668-05-7**
RL: PROC (Process)
(conversion of, to bismuth salt)

RN 62668-05-7 CAPLUS
CN Pentanoic acid, 5-[(2-amino-4-pyrimidinyl)amino]-5-oxo- (9CI) (CA INDEX NAME)



IT **62668-06-8P 62668-08-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 62668-06-8 CAPLUS
CN Pentanoic acid, 5-[(2-amino-4-pyrimidinyl)amino]-5-oxo-, bismuth salt (9CI) (CA INDEX NAME)





RN 62668-08-0 CAPLUS

CN Butanoic acid, 4-[[2-amino-5-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-4-oxo-, bismuth salt (9CI) (CA INDEX NAME)



●x Bi(x)

IT **62668-07-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with pyrimidinediamine carboxyacyl derivs.)
RN 62668-07-9 CAPLUS
CN Butanoic acid, 4-[[2-amino-5-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L16 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1977:189848 CAPLUS
DN 86:189848
TI Synthesis of compounds related to antitumor agents. V. On the reaction of aliphatic carboxylates with 2,4-diamino-5-hydroxy-6-methylpyrimidine
AU Kato, Tetsuo; Oda, Noriichi; Ito, Isoo
CS Fac. Pharm. Sci., Nagoya City Univ., Nagoya, Japan
SO Chemical & Pharmaceutical Bulletin (1977), 25(3), 491-4
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
AB 2,4-Diamino-5-hydroxy-6-methylpyrimidine (I) was treated with CH2(CO2Et)2 at 140-50.degree. to give pyrimidine II (R = OH, R1 = OEt, R2 = CH2CO2Et) which was treated with HOAc at 40-50.degree. for 10 min to give a mixt. of pyrimido[5,4-d][1,4]oxazepine III (R3 = OH, R4 = OEt, R5 = Ac) (IV) and dihydrooxazolo[4,5-d]pyrimidine V. IV was refluxed in EtOH for 8 h to give III (R3R4 = O, R5 = Ac) which was deacetylated and lactone-cleaved by hydrolysis with 10% HCl. The resulting hydroxy acid deriv. was recyclized in Me2SO at 140-150.degree. for 20 min. to give III (R3R4 = O, R5 = H). Pyrimido[5,4-b]oxazine VI, oxazolo[4,5-d]pyrimidine VII, and II [RR1 = O, R2 = CH2CH2CO2R6 (R6 = Me, Et)] were also prepd. from I.
IT **62812-12-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and lactonization of)
RN 62812-12-8 CAPLUS
CN Propanoic acid, 3-[(2-amino-5-hydroxy-6-methyl-4-pyrimidinyl)amino]-3-oxo- (9CI) (CA INDEX NAME)



L16 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1975:588142 CAPLUS
DN 83:188142
TI Metabolism of minoxidil, a new hypotensive agent. II. Biotransformation following oral administration to rats, dogs, and monkeys
AU Thomas, Richard C.; Harpootlian, Harry
CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA
SO Journal of Pharmaceutical Sciences (1975), 64(8), 1366-71
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
AB The biotransformation of minoxidil (I) [38304-91-5] was studied in the rat, dog, and monkey and compared to reported results in the human. Each species excreted substantially the same metabolites, but in quite different relative amts. The monkey and the human exhibited similar metabolite profiles, whereas the dog and rat were quant. different from each other and from the monkey and human. The major excretory product for the monkey and human was I glucuronide [56828-40-1]. Substantially smaller amts. of unchanged I, 2,4-diamino-6-(4'-hydroxypiperidino)pyrimidine 3-oxide [56828-37-6], and more polar metabolites also were excreted by these 2 species. The major excretory product in the rat was unchanged I. Almost as much (combined) of the 2 acidic metabolites, 2,4-diamino-6-(4'-carboxy-n-butylamino)pyrimidine [**56828-38-7**] and its 3-oxide [**56828-41-2**], also were produced. Smaller amts. of the glucuronide of I, 2,4-diamino-6-(4'-hydroxypiperidino)pyrimidine 3-oxide, its 3'-hydroxy isomer [56828-39-8], and 2,4-diamino-6-piperidinopyrimidine [24867-26-3] also were excreted by the rat. The major metabolite of I excreted by the dog was the 4'-hydroxy metabolite. Smaller amts. of unchanged I and polar metabolites and much smaller amts. of the glucuronide of I, the 3'-hydroxy metabolite, and 2,4-diamino-6-piperidinopyrimidine also were excreted by the dog. Evidence was obtained for a 4'-hydroxy metabolite glucuronide in this species. The major circulatory material in dog plasma was the 4'-hydroxy metabolite, whereas it was the glucuronide of I in monkey plasma.
IT **56828-38-7 56828-41-2**
RL: BIOL (Biological study)
(as minoxidil metabolite, species in relation to)
RN 56828-38-7 CAPLUS
CN Pentanoic acid, 5-[(2,6-diamino-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



Same as #17

RN 56828-41-2 CAPLUS
CN Pentanoic acid, 5-[(2,6-diamino-1-oxido-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)


H2N
N
NH— (CH2) 4 — CO2H
N
O
NH2

L16 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1975:38479 CAPLUS
DN 82:38479
TI Synthesis and antifolate activity of isoaminopterin
AU Nair, M. G.; Mercer, L. P.; Baugh, Charles M.
CS Dep. Biochem., Univ. South Alabama, Mobile, AL, USA
SO Journal of Medicinal Chemistry (1974), 17(12), 1268-72
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB Isoaminopterin (I) [53661-94-2], a candidate antitumor agent, inhibited growth of folate-requiring Lactobacillus casei and Streptococcus faecium at ED50 0.90 .times. 10-13 and 45 .times. 10-13M, resp., and inhibited dihydrofolate reductase [9002-03-3] from L. casei by 50% at 14.5 .times. 10-9M. These were similar to the effective concns. of methotrexate [59-05-2]. I was prepd. by a modification of the isofolic acid synthesis by W. R. Boon and T. Leigh (1951), or by an alternate procedure involving coupling of 6-chloro-2,4-diaminopteridine [17714-06-6] with .alpha.-amino-p-toluic acid [56-91-7].
IT **53661-96-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of)
RN 53661-96-4 CAPLUS
CN Benzoic acid, 4-[[[[(2,5,6-triamino-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



IT **53661-95-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and redn. of)
RN 53661-95-3 CAPLUS
CN Benzoic acid, 4-[[[[(2,6-diamino-5-nitro-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1974:146111 CAPLUS
DN 80:146111
TI Pteridines. LX. Synthesis and autoxidation of 7,8-dihydroxanthopterins
AU Pfleiderer, Wolfgang
CS Fachbereich Chem., Univ. Konstanz, Constance, Fed. Rep. Ger.
SO Chemische Berichte (1974), 107(3), 785-95
CODEN: CHBEAM; ISSN: 0009-2940
DT Journal
LA German
AB Reaction of the chloropyrimidines I with R3NHCR4R5CO2Et and ring closure of the resulting aminopyrimidines II gave the title xanthopterins III (R1-R5 = H or Me, R6 = H). Similarly prepd. was III (R1-R5 = H, R6 = Me). The pKa values and uv spectra were detd. The monoanions of III were subject to autoxidn., which was catalyzed by NH3 and primary angles.
IT **1154-85-4P 14508-66-8P 14699-57-1P**
52296-01-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 1154-85-4 CAPLUS
CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14508-66-8 CAPLUS
CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAPLUS
CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 52296-01-2 CAPLUS
CN L-Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1974:128131 CAPLUS
DN 80:128131
TI Synthesis and biological evaluation of isofolic acid
AU Nair, M. G.; Baugh, Charles M.
CS Nutr. Program, Univ. Alabama, Birmingham, AL, USA
SO Journal of Medicinal Chemistry (1974), 117(2), 223-6
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB Isofolic acid (I) [52560-13-1] was prepd. by displacement reaction of N-glycyl-.alpha.-amino-p-toluic acid [51542-05-3] with 2-amino-6-chloro-5-nitro-4(3H)-pyrimidinone [1007-99-4], dithionite redn. of the nitro group, thermal cyclization, and MnO2 oxidn. to isopteroic acid (II) [51542-06-4], which was coupled with di-Et glutamate by the mixed anhydride method. I and II were comparable to methotrexate [59-05-2] as inhibitors of Streptococcus faecium, while Lactobacillus casei was inhibited by I but not by II. The implications of the use of II as a specific inhibitor of organisms capable of attaching the terminal glutamyl moiety to the mol. were discussed.
IT **52121-32-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 52121-32-1 CAPLUS
CN Benzoic acid, 4-[[[[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



IT **52121-33-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(thermal cyclization of)
RN 52121-33-2 CAPLUS
CN Benzoic acid, 4-[[[[(2,5-diamino-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



L16 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1974:37077 CAPLUS
DN 80:37077
TI Synthesis and electrophilic bromination of 2-methyl-9-carbethoxy-1,3,4,7-tetraazacycl[3.3.3]azine
AU Ceder, Olof; Rosen, Kenneth
CS Chalmers Inst. Technol., Univ. Goteborg, Goteborg, Swed.
SO Acta Chemica Scandinavica (1947-1973) (1973), 27(7), 2421-5
CODEN: ACSAA4; ISSN: 0001-5393
DT Journal
LA English
AB 1,3,4,7-Tetraazacycl[3.3.3]azine (I, R = H) was prepd. from 2,4-diaminopyrimidine and EtOCH:C(CN)CO2Et. Electrophilic bromination of I (R = H) gave I (R = Br).
IT **51138-31-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 51138-31-9 CAPLUS
CN 2-Propenoic acid, 3-[(2-amino-4-pyrimidinyl)amino]-2-cyano-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1967:85762 CAPLUS
DN 66:85762
TI Synthesis of some N-methylated pteridines related to 7,8-dihydroxanthopterin
AU Zondler, Helmut; Forrest, Hugh S.; Lagowski, Jeanne M.
CS Univ. of Texas, Austin, TX, USA
SO Journal of Heterocyclic Chemistry (1967), 4(1), 12-15
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
AB Seven methylated pteridines were synthesized by condensation of a 4-chloro-5-nitropyrimidine with a .beta.-oxoamine (or a blocked deriv.), redn. of the nitro group, and subsequent ring closure. This scheme provides a new route to dihydroxanthopterin (I). Several cases are reported, however, in the uracil series where ring closure could not be effected.
IT **14508-66-8P 14699-57-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 14508-66-8 CAPLUS
CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAPLUS
CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1965:29707 CAPLUS
DN 62:29707
OREF 62:5278h,5279a-b
TI Pteridine derivatives. IX. 2,6-Diamino-4-hydroxypteridine and related dihydropteridines
AU Stuart, Alexander; West, D. W.; Wood, H. C. S.
CS Roy. Coll. Sci. Technol., Glasgow, UK
SO J. Chem. Soc. (1964), (Dec.), 4769-74
DT Journal
LA English
AB cf CA 55, 11422i. An unambiguous synthesis of 2,6-diamino-4-hydroxypteridine is described and the product is shown to be identical with a specimen isolated by van Baalen and Forrest (CA 53, 15089a) from blue-green algae. The structure of some related dihydropteridines is examd., and in particular the structure of 7,8-dihydroxanthopterin (I) is confirmed.
IT **1140-88-1**, Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- **1154-85-4**, Alanine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-2-methyl-, ethyl ester **14699-57-1**, Glycine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, ethyl ester
(prepn. of)
RN 1140-88-1 CAPLUS
CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI) (CA INDEX NAME)



RN 1154-85-4 CAPLUS
CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAPLUS
CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1965:29706 CAPLUS
DN 62:29706
OREF 62:5278f-h
TI Chemical and kinetic studies on the reaction of 2-hydrazino-3-phenylquinoxaline with carbonyl compounds. I
AU Tagami, Shoichiro; Shiho, Denitsu
CS Univ. Toyama, Japan
SO Yakugaku Zasshi (1964), 84(11), 1085-90
DT Journal
LA Japanese
AB A mixt. of 6.0 g. 2-chloro-3-phenylquinoxaline, 17 g. MeNH2.HCl, 13 g. Na2CO3, and 50 ml. EtOH is heated 7 hrs. in an autoclave at 100-50.degree. to give 5.8 g. 2-methylamino-3-phenylquinoxaline (I), pale yellow needles, m. 132.degree. (dil. MeOH). I (4.8 g.) in 400 ml. H2O is treated overnight with 80 ml. concd. HCl and 2.4 g. NaNO2 and the resulting nitrosoamine compd. (pale yellow needles, m. 109.5.degree. (Me2CO)) (1.31 g.) is reduced in 70 ml. Et2O by using 20 ml. ethereal soln. of 0.19 g. LiAlH4 to give 2-(1-methylhydrazino)-3-phenylquinoxaline (II); HCl salt m. 245.degree. (decompn.). II (0.25 g.) is dissolved in a small amt. of EtOH and kept at room temp. with 0.0015 mole aldehyde to give the following III (R and m.p. given): Ph, 181.5.degree.; p-ClC6H4, 115.degree.; p-NO2C6H4, 171.degree.. Pyrolysis of III gives the corresponding 1-substituted s-triazolo [4,3-a] quinoxaline with concurrent elimination of a hydrocarbon. Factors which apparently govern the elimination of alkyl groups from III are discussed. Also, the kinetic of the pyrolysis reaction are studied and the mechanisms for this type of cleavage presented.
IT **1140-88-1**, Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- **1154-85-4**, Alanine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-2-methyl-, ethyl ester **14699-57-1**, Glycine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, ethyl ester
(prepn. of)
RN 1140-88-1 CAPLUS
CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI) (CA INDEX NAME)

Same as #30



RN 1154-85-4 CAPLUS
CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAPLUS
CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1964:486219 CAPLUS
DN 61:86219
OREF 61:15066h,15067a-c
TI Effect of a number of N-pyrimidyl amino acids and of some of their 5-arylazo derivatives on the growth of certain microorganisms
AU Roy-Burman, P.; Sen, D.
CS Univ. Coll. Sci. Technol., Calcutta
SO Biochem. Pharmacol. (1964), 13(10), 1437-49
DT Journal
LA Unavailable
AB Sixteen new N-pyrimidyl amino acids were obtained by substitution at the C-2, C-4, or C-6 position of 2,4-diamino-6-methylpyrimidine by aromatic amino acids or different carboxyalkyl amino groups (i.e., aliphatic amino acid moiety). These compds. were tested for their effect on the growth of Streptococcus faecalis, Lactobacillus arabinosus, and Escherichia coli. The new compds., 2,4-diamino-5-arylazo-6-methylpyrimidine and six N-(5-arylazo-4-pyrimidyl) amino acids, were also studied. 2,4-Diamino-6-methylpyrimidine inhibited growth of all 3 microorganisms tested, but substitution at the C-2, C-4, or C-6 position by carboxyalkyl amino groups produced compds. with little or no inhibitory effects. The three N-pyrimidyl compds. substituted with aromatic amino acids inhibited growth but were less effective than the parent compd. All the 5-arylazopyrimidines significantly inhibited growth of S. faecalis and, to a lesser extent, L. arabinosus. It was observed that among these compds. the inhibitory activity decreased with increase in the bulk of the amino acid moiety. Investigation of the mechanism of the inhibitory action of these compds. in S. faecalis revealed that they acted primarily as folic acid antagonists in a manner consistent with an assumption that they interfere with the enzymic conversion of folic acid to N5-formyltetrahydrofolic acid in S. faecalis.
IT **93727-00-5**, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- **94093-95-5**, Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- **94264-54-7**, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylbutyl)amino]-6-methyl-5-pyrimidinyl]azo]- **96063-58-0**, Benzoic acid, p-[2-amino-4-[(.alpha.-carboxyphenethyl)amino]-6-methyl-5-pyrimidinyl]azo]-
(bactericidal activity of)
RN 93727-00-5 CAPLUS
CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94093-95-5 CAPLUS
CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94264-54-7 CAPLUS
CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAPLUS
CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)



IT **89465-54-3**, Glycine, N-(2,6-diamino-4-pyrimidinyl)-
89897-36-9, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-
90198-25-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-
90198-46-2, Serine, N-(2-amino-6-methyl-4-pyrimidinyl)-
90649-20-0, Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- **91253-20-2**, Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- **91253-21-3**, Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- **91717-29-2**, Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- **92296-32-7**, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl-
(prepn. and bactericidal activity of)
RN 89465-54-3 CAPLUS
CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 89897-36-9 CAPLUS
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-25-7 CAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-46-2 CAPLUS
CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90649-20-0 CAPLUS
CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)



RN 91253-20-2 CAPLUS
CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91253-21-3 CAPLUS
CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91717-29-2 CAPLUS
CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)



L16 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1964:60902 CAPLUS
DN 60:60902
OREF 60:10680g-h,10681a-b
TI Pyrimidines. IV. Derivatives of 2-amino-4-methyl-6-hydroxypyrimidine
AU Fel'dman, I. Kh.
SO Tr. Leningr. Khim.-Farmatsevt. Inst. (1962), (16), 25-8
DT Journal
LA Unavailable
AB cf. CA 55, 21136c, 23544f. For chem. and biol. study, a series of derivs. of I (R = OH) (Ia) was obtained. Ia (14.5 g.) and 30 ml. POCl3 were heated at 100.degree. 3 hrs., excess POCl3 removed under vacuum, ice, added, and NH4OH added to ppt. I (R = Cl) (Ib), 89%, m. 180-2.degree. (C2H4Cl2); Ac deriv. formed. I (R = SH) (Ic) treated with Ac2O gave the Ac deriv. of Ic, C7H9N3OS, m. 133-4.degree. (50% alc.). Ia (5 g.), 10 ml. ethylene oxide, and 15 ml. water were heated in a sealed tube at 50.degree. 10 hrs. to give 1-(.beta.-hydroxyethyl)-2-amino-4-methyldihydro-6-pyrimidinone, yield 68%, m. 187-8.degree. (1:2 alc.-ether), 1.69 g. of which and 1 ml. SOCl2 were heated to soln. and cooled to give 1-(.beta.-chloroethyl)-2-amino-4-methyldihydro-6-pyrimidinone-HCl, yield 62%, m. 215-16.degree. (alc.). To a soln. of Ia (0.625 g.) in 3 ml. 15% NaOH with cooling, 0.8 g. MeSO2Cl is added to give I (R = MeSO3), 70%, m. 138-9.degree. (alc.). A mixt. of 1.4 g. Ib and 10 ml. BuOH was heated to soln., 1.05 g. HN-(CH2CH2OH)2 added, and the mixt. stirred at 130-40.degree. 6 hrs. to give I.HCl [R = N(CH2CH2OH)2] (Id), 80%, m. 165-6.degree. (Me-OH). Id (2.5 g.) and 15 ml. dichloroethane was treated with cooling with 3 ml. SOCl2 dropwise, and the mixt. heated at 80.degree. 20 min. and kept several hrs. to give I.HCl [R = N(CH2CH2Cl)2], yield 93%, m. 214-15.degree. (MeOH). Ib (5.72 g.), 9 g. H2NCH2CO2H, 2 g. Et3N, and 25 ml. HCONMe2 was stirred 80-5 hrs. at 90-100.degree. to give I.HCl (R = NHCH2CO2H), m. 171-3.degree. (alc.). Ib (2.86 g.), 2 ml. H2NCH2CO2Et, and 13 ml. HCONMe2 was heated at 70-80.degree. 68-70 hrs. to give I.HCl (R = NHCH2CO2Et), m. 218-19.degree. (alc.).
IT **92385-16-5**, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride **93263-85-5**, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride
(prepn. of)
RN 92385-16-5 CAPLUS
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride (7CI) (CA INDEX NAME)



not 102

●x HCl

RN 93263-85-5 CAPLUS
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

L16 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1964:9987 CAPLUS
DN 60:9987
OREF 60:1829e-g
TI Potential antimetabolites. VII. Substituted N-4-pyrimidyl amino acids and their derivatives
AU Shvachkin, Yu. P.; Berestenko, M. K.
CS State Univ., Moscow
SO Zh. Obshch. Khim. (1963), 33(9), 2842-8
DT Journal
LA Unavailable
AB cf. CA 58, 3425a; 60, 654e. The following were prepd. as potential antimetabolites in protein-nucleic metabolism. PhCH2CH(NH2)CO2H refluxed in aq. NaOH with 2-amino-4chloro-5-nitro-6-methylpyrimidine (I) 40 min. gave after treatment with AcOH 72.8% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)phenylalanine, decompd. 219-20.degree., .LAMBDA. 260 and 368-72 m.mu.; also formed in 41.7% yield from the corresponding Me ester (II) refluxed 3 hrs. in 2N HCl. Di-Na glutamate similarly gave 82.7% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)glutamic acid, decompd. 213-14.degree., .LAMBDA. 367-9 m.mu.. Similarly, arginine gave 53.6% .alpha.-N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)arginine, m. 203-5.degree., .LAMBDA. 362-4 and 364-5 m.mu.. Phenylalanine Me ester-HCl treated with MeONa-MeOH at 0.degree., then with I, finally at room temp. 40 min., gave 54.2% II, m. 173.degree., .LAMBDA. 260-1 and 358 m.mu., which also formed by esterifying the free amino acid with MeOHHCl 3 hrs. at reflux and 12 hrs. at room temp. in 92.1% yield. Similarly tyrosine Me ester-HCl and I in MeONa-MeOH-Me2CO gave in 0.5 hr. at 0.degree. and 1 hr. at room temp. 54.6% N-(2-amino5-nitro-6-methyl-4-pyrimidyl)tyrosine Me ester, m. 173.degree., .LAMBDA. 259 and 361-3 m.mu.. Similarly were prepd.: N-(2-amino-5-nitro-6methyl-14-pyrimidyl) valine Me ester, 70.4%, m. 163.degree., 259 and 362-5 m.mu.; N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)leucine Me ester, 65, m. 153.degree., .LAMBDA. 261 and 360 m.mu.; N-(2-amino-5-nitro-6methyl-4-pyrimidyl)glutamic acid di-Me ester, 46.7, m. 112.degree., .LAMBDA. 257-9 and 360 m.mu.; N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)phenylalanylglycine Me ester, 58, m. 170-1.degree. (MeOH), .LAMBDA. 262 and 362-3 m.mu.. The electrophoretic mobilities in 30% AcOH or in 0.1N borax are reported, as are the Rf values on paper in isoPrOH-NH4OH-H2O, BuOH-H2O-AcOH, and BuOH satd. with H2O.
IT **91194-85-3**, Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester **92286-86-7**, Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- **93002-46-1**, Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester **93537-11-2**, Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester **94823-79-7**, Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl)-, methyl ester
(prepn. of)
RN 91194-85-3 CAPLUS
CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 92286-86-7 CAPLUS
CN Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 93002-46-1 CAPLUS
CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 93537-11-2 CAPLUS
CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAPLUS
CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1963:462818 CAPLUS
DN 59:62818
OREF 59:11651c-d
TI Structure of proteins. VIII. Preparation of nitropyrimidylamino acids
AU Scoffone, Ernesto; Signor, Angelo; Biondi, Laura
CS Univ. Padua, Italy
SO Gazz. Chim. Ital (1963), 93(1-2), 81-9
DT Journal
LA Unavailable
AB 2-Chloro-5-nitro- (I), 2-methyl-4-chloro-5-nitro-6-amino-(II), and 2-amino-4-chloro-5-nitro-6-methylpyrimidine (III) were similarly treated with amino acids (amino acid and m.p. derivs. with I, II, III given): glycine, 188.degree., 290.degree., 240.degree.; DL-alanine, 187.degree., 253.degree., 230.degree.; DL-serine, 208.degree., 240.degree., 220.degree.; DL-valine, 151.degree., --, 220.degree.; L-leucine, 94.degree., 240.degree., --; DL-phenylalanine, 193.degree., 236.degree., 210.degree.; L-proline (IV), 178.degree., 260.degree., 135.degree.; L-tyrosine --, --, 164.degree.. All I derivs. had .lambda. useful for detn. at 340 .+-. 2 m.mu. (except IV, 360 m.mu.), II derivs., at 345 m.mu. (IV, 340 m.mu.), and III derivs., at 361 m.mu. (IV 380 m.mu.) and 260 m.mu. (IV, 274 m.mu.). The stability of these derivs. was greater than of the pyridine derivs.; leucine and phenylalanine derivs. with II gave a 0% hydrolysis test. II is the preferred reagent.
IT **89854-39-7**, Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (prepn. of)
RN 89854-39-7 CAPLUS
CN Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L16 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1963:73327 CAPLUS
DN 58:73327
OREF 58:12559b-c
TI Synthesis of some N-pyrimidylamino acids. III
AU Roy-Burman, P.; Sen, D.
CS Univ. Colls. Sci. Technol., Calcutta
SO Naturwissenschaften (1962), 49, 494-5
DT Journal
LA English
AB cf. CA 57, 824b. The following were prepd.: I [R = CH(CH2OH)CO2H], m. 213-14.degree. (decompn.), .lambda. 270 m.mu.; I (R = C6H4CO2H-p), chars without melting 338-40.degree., .lambda. 300 m.mu.; I (R = CH2CONHNH2), m. 205-9.degree., .lambda. 270 m.mu.; II (R = C6H4CO2H-p), m. 312.degree. (decompn.) .lambda. 272 and 310 m.mu.; II (R = C6H4SO3H-p, m. >360.degree., .lambda. 265 and 305 m.mu.; and III (R = CH2CO2H), m. >360.degree., .lambda. 275 m.mu..
IT **89465-54-3**, Glycine, N-(2,6-diamino-4-pyrimidinyl)-
(prepn. of)
RN 89465-54-3 CAPLUS
CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L16 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1963:48342 CAPLUS
DN 58:48342
OREF 58:8252g-h,8253a
TI N-(5-Arylazo-4-pyrimidyl)amino acids as growth inhibitors of Streptococcus faecalis
AU Roy-Burman, P.; Sen, D.
CS Univ. Calcutta
SO Nature (1962), 196, 1316
DT Journal
LA Unavailable
AB cf. Tanaka, et al., CA 54, 21111g. Seven new compds. were prepd. (CA 55, 10456f) and their inhibitory action tested on certain microorganisms. All the compds. inhibited the growth of S. faecalis, and all were competitive antagonists to pteroylglutamic acid (PGA) and leucovorin. Inhibition of S. faecalis was as follows: (concn. .gamma./ml. required for 50% inhibition of growth in the presence of PGA (0.001 .gamma./ml.)): I, 0.105; II (R = H), 1.07; II (R = Me) 2.25; II (R = Et), 2.7; II (R = iso-Pr), 7.19; II (R = sec-Bu), 7.8; II (R: benzyl), 22.8.
IT **94264-54-7**, Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]-
(Staphylococcus faecalis response)
RN 94264-54-7 CAPLUS
CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



IT **93727-00-5**, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- **94093-95-5**, Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- **94264-54-7**, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylbutyl)amino]-6-methyl-5-pyrimidinyl]azo]- **96063-58-0**, Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]-
(Staphylococcus faecalis response to)
RN 93727-00-5 CAPLUS
CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94093-95-5 CAPLUS
CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94264-54-7 CAPLUS
CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAPLUS
CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)



L16 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1963:20731 CAPLUS
DN 58:20731
OREF 58:3425a-c
TI Nucleophilic displacement reactions in the synthesis of N-4-pyrimidyl amino acids and their derivatives
AU Shvachkin, Yu. P.; Berestenko, M. K.
CS State Univ., Moscow
SO Zh. Obshch. Khim. (1962), 32, 1712-13
DT Journal
LA Unavailable
AB Reaction of 2-amino-4-chloro-5-nitro-6-methylpyrimidine with Na salts or esters of amino acids readily gave I (R given): HO2CCH(CH2Ph), decompg. at 219-20.degree.; HO2CCH(CH2CH2CO2H), decompg. at 213-14.degree.; MeO2CCH(CH2Ph), m. 173.degree.; MeO2CCH(CH2CH2CO2Me), m. 112.degree. MeO2CCH(CHMe2), m. 163.degree.; MeO2CCH(CH2CHMe2), m. 153.degree.; MeO2CCH(CH2C6H4OH-p), m. 173.degree.; MeO2CCH2NHCOCH(CH2Ph), m. 170.degree.. The yields were 46-83%. Ultraviolet max. were given.
IT **91194-85-3**, Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester **92295-36-8**, Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- **92556-22-4**, Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester **93002-46-1**, Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester **93537-11-2**, Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester **94823-79-7**, Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl)-, methyl ester
(prepn. of)
RN 91194-85-3 CAPLUS
CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 92295-36-8 CAPLUS
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)



RN 92556-22-4 CAPLUS
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)



RN 93002-46-1 CAPLUS
CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 93537-11-2 CAPLUS
CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAPLUS
CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1962:404013 CAPLUS
DN 57:4013
OREF 57:824b-e
TI Synthesis of some N-pyrimidyl amino acids. II
AU Roy-Burman, P.; Len, D.; Guha, B. C.
CS Univ. Colls. Sci. and Technol., Calcutta
SO Naturwissenschaften (1961), 48, 737
DT Journal
LA English
AB cf. CA 55, 10456f. Various substituted carboxyalkylaminopyrimidines (I) were prepd. to give compds. with possible effect on tumor growth and on the growth of various microorganisms. The following I were obtained [R, R', m.p. (decompn.), .lambda. (detd. in 0.1N HCl), and type (L or DL) given]: H, CH(CO2H)CH2CHMe2 (I), 278.degree., 270, L; H, CH(CO2H)CHMeEt (II), 276-8.degree., 270, DL; H, CH(CO2H)Et (III), 284-6.degree., 270, DL; CH2(CO2H), H (IV), 289-92.degree. (vacuum sealed capillary), 270, -; CH(CO2H)Me, H (V), 222-5.degree., 209, DL; CH(CO2H)2CH2Ph, H (VI), 260-3.degree., 270, DL; H, CH(CO2Et)CH2CHMe2 (VII), 119-20.degree. (no decompn.), -, -; CH2(CO2Et), H (VIII), 136-7.5.degree. (no decompn.), -, -. I-VI (white, amphoteric compds.) were prepd. by condensation of 2-amino-4-chloro-6-methylpyrimidine or of 2-chloro-4amino-6-methylpyrimidine with equimolar amts. of amino acids in an aq. medium in the presence of small amts. of HCl, VII and VIII by passing dry HCl through an EtOH suspension (heated to 80.degree.) of I and II, resp., followed by treatment with aq. Na2CO3. III, IV, and V were purified by crystn. from H2O, I, II, VI by dissolving in ammonia and pptg. by addn. of HCl to pH 6-7.degree., VII and VIII by dissolving in EtOH and pptg. with H2O.
IT **92107-70-5**, Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester
(prepn. of)
RN 92107-70-5 CAPLUS
CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 40 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1961:54318 CAPLUS
DN 55:54318
OREF 55:10456f-g
TI N-Pyrimidyl amino acids
AU Roy-Burman, P.; Roy, Dolly; Sen, D.
CS Univ. Colls. Sci. Technol., Calcutta
SO Naturwissenschaften (1960), 47, 515-16
DT Journal
LA English
AB 2-Amino-4-chloro-6-methylpyrimidine was condensed with equimolar amts. of amino acids in an aq. medium in the presence of small amts. of HCl. The 2-amino-4-chloro-6-methylpyrimidyl derivs. of the following were prepd. and recrystd. from H2O [m.p. (decompn.) given]: glycine, 298.degree.; DL-alanine, 290.degree.; DL-phenylalanine, 275.degree.; DL-valine, 287.degree.; DL-serine, 264.degree.. The ultraviolet absorption of these compds. showed a peak near 270 m.mu. (in 0.1N HCl).
IT **89897-36-9**, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-
90198-25-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-
92296-32-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl-
(prepn. of)
RN 89897-36-9 CAPLUS
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-25-7 CAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 18:19:19 ON 21 FEB 2003)

     FILE 'REGISTRY' ENTERED AT 18:19:25 ON 21 FEB 2003
L1              STRUCTURE UPLOADED
L2           21 S L1 SSS SAM
L3              SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045
L4              STRUCTURE UPLOADED
L5              QUE L4 NOT L3
L6           50 S L5 SSS SAM
L7              SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045
L8              STRUCTURE UPLOADED
L9              QUE L8 NOT L7
L10          50 S L9 SSS SAM
L11             SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045
L12             STRUCTURE UPLOADED
L13             QUE L12 NOT L11
L14           3 S L13 SSS SAM
L15          88 S L13 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:31:01 ON 21 FEB 2003
L16          40 S L15

     FILE 'CAOLD' ENTERED AT 18:31:52 ON 21 FEB 2003

=> s l15
L17          12 L15

=> d l17 1-12 bib,hitstr
```

L17 ANSWER 1 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA62:5278h CAOLD
TI pteridine derivs. - (IX) 2,6-diamino-4-hydroxypteridine and related dihydropteridines
AU Stuart, Alexander; West, D. W.; Wood, H. C. S.
IT **1140-88-1 1154-85-4 14699-57-1**
RN 1140-88-1 CAOLD
CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI) (CA INDEX NAME)



RN 1154-85-4 CAOLD
CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAOLD
CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 2 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA61:15067a CAOLD
TI effect of a number of N-pyrimidyl amino acids and of some of their 5-arylazo derivs. on the growth of certain microorganisms
AU Roy-Burman, P.; Sen, D.
IT **89465-54-3 89897-36-9 90198-25-7**
90198-46-2 90649-20-0 91253-20-2
91253-21-3 91717-29-2 92296-32-7
93432-76-9 93727-00-5 94093-95-5
94264-54-7 95126-82-2 96063-58-0
RN 89465-54-3 CAOLD
CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 89897-36-9 CAOLD
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-25-7 CAOLD
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-46-2 CAOLD
CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90649-20-0 CAOLD
CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)



RN 91253-20-2 CAOLD
CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91253-21-3 CAOLD
CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91717-29-2 CAOLD
CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAOLD
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)



RN 93432-76-9 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(carboxymethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 93727-00-5 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94093-95-5 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94264-54-7 CAOLD
CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



RN 95126-82-2 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(1-carboxyethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAOLD
CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)



L17 ANSWER 3 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA60:10681b CAOLD
TI synthesis of some simple 2-substituted pyrimidines and 2,2'-bipyrimidines, and their anal. applications
AU Bly, Donald D.; Mellon, M. G.
IT **92385-16-5 93263-85-5**
RN 92385-16-5 CAOLD
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

RN 93263-85-5 CAOLD
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

L17 ANSWER 4 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA60:1829g CAOLD
TI potential antimetabolites - (VIII) acyclic amino acids from pyrimidines
AU Shvachkin, Yu. P.; Syrtsova, L. A.
IT **91194-85-3 91647-59-5 93002-46-1**
94823-79-7
RN 91194-85-3 CAOLD
CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 91647-59-5 CAOLD
CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, dimethyl ester (7CI) (CA INDEX NAME)



RN 93002-46-1 CAOLD
CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAOLD

CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L17 ANSWER 5 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA60:1829e CAOLD
TI potential antimetabolites - (VII) substituted N-(4-pyrimidyl)amino acids and their derivs.
AU Shvachkin, Yu. P.; Berestenko, M. K.
IT **91086-76-9 92286-86-7 92295-36-8 92556-22-4 93537-11-2**
RN 91086-76-9 CAOLD
CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 92286-86-7 CAOLD
CN Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 92295-36-8 CAOLD
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)



RN 92556-22-4 CAOLD
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)



RN 93537-11-2 CAOLD
CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



L17 ANSWER 6 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA59:11651c CAOLD
TI structure of proteins - (VIII) prepn. of nitropyrimidylamino acids
AU Scoffone, Ernesto.; Signor, A.; Biondi, L.
IT **89854-39-7 90085-29-3 91978-49-3**
92295-36-8 92295-39-1 92347-91-6
RN 89854-39-7 CAOLD
CN Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 90085-29-3 CAOLD
CN Serine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91978-49-3 CAOLD
CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 92295-36-8 CAOLD
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)



RN 92295-39-1 CAOLD
CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 92347-91-6 CAOLD
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L17 ANSWER 7 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA58:12559b CAOLD
TI synthesis of some N-pyrimidyl amino acids - (III)
AU Roy-Burman, P.; Sen, D.
IT **89465-54-3**
RN 89465-54-3 CAOLD
CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L17 ANSWER 8 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA58:8252h CAOLD
TI N-(5-arylazo-4-pyrimidyl)amino acids as growth inhibitors of Streptococcus faecalis
AU Roy-Burman, P.; Sen, D.
IT **93432-76-9 93727-00-5 94093-95-5 94264-54-7 95126-82-2 96063-58-0**
RN 93432-76-9 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(carboxymethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 93727-00-5 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94093-95-5 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 94264-54-7 CAOLD
CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



RN 95126-82-2 CAOLD
CN Benzoic acid, p-[[2-amino-4-[(1-carboxyethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAOLD
CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)



L17 ANSWER 9 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA58:3425a CAOLD
TI nucleophilic displacement reactions in the synthesis of N-(4-pyrimidyl)amino acids and their derivs.
AU Shvachkin, Yu. P.; Berestenko, M. K.
TI sulfanilamidopyrimidines - (II) 4-sulfanilamidopyrimidines and certain 4,6-disubstituted pyrimidines
AU Taft, William E.; Shepherd, R. G.
IT **91086-76-9 91194-85-3 91647-59-5 92295-36-8 92556-22-4 93002-46-1 93537-11-2 94823-79-7**
RN 91086-76-9 CAOLD
CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91194-85-3 CAOLD
CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 91647-59-5 CAOLD
CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, dimethyl ester (7CI) (CA INDEX NAME)



RN 92295-36-8 CAOLD
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)



RN 92556-22-4 CAOLD
CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)



RN 93002-46-1 CAOLD
CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 93537-11-2 CAOLD
CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAOLD
CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L17 ANSWER 10 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA57:824b CAOLD
TI synthesis of some N-pyrimidyl amino acids - (II)
AU Roy-Burman, P.; Sen, D.; Guha, B. C.
IT **90649-20-0 91253-20-2 91253-21-3**
92107-70-5
RN 90649-20-0 CAOLD
CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)



RN 91253-20-2 CAOLD
CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91253-21-3 CAOLD
CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 92107-70-5 CAOLD
CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)


H2N
N
Me
N
NH— CH— Bu-i
C— OEt
O

L17 ANSWER 11 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA55:10456g CAOLD
TI structure of muta-aspergillic acid
AU Nakamura, Seiji
IT **89897-36-9 90198-25-7 90198-46-2**
91717-29-2 92296-32-7
RN 89897-36-9 CAOLD
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-25-7 CAOLD
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 90198-46-2 CAOLD
CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 91717-29-2 CAOLD
CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAOLD
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA

INDEX NAME)



L17 ANSWER 12 OF 12 CAOLD COPYRIGHT 2003 ACS
AN CA54:7712i CAOLD
TI hydropteridines - (V) 7,8-dihydro-6-hydroxy-4-pteridinecarboxylic acids
AU Clark, Jim; Layton, A. J.
IT **99988-33-7 100140-57-6**
RN 99988-33-7 CAOLD
CN 4-Pyrimidinecarboxylic acid, 2-amino-6-[(carboxymethyl)amino]-5-nitro-, diethyl ester (6CI) (CA INDEX NAME)



RN 100140-57-6 CAOLD
CN 4-Pyrimidinecarboxylic acid, 2,5-diamino-6-[(carboxymethyl)amino]-, diethyl ester (6CI) (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY      SESSION
FULL ESTIMATED COST                           31.84       369.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY      SESSION
CA SUBSCRIBER PRICE                            0.00       -26.04

STN INTERNATIONAL LOGOFF AT 18:32:33 ON 21 FEB 2003
```